Pseudomonas aeruginosa is frequently resistant to multiple antibiotics, including aminoglycosides. The rates of resistance to aminoglycosides in bloodstream isolates collected over 2 decades at a United States hospital remained constant, suggesting that antibiotic stewardship programs may be effective in countering an increase in resistance.

Pseudomonas aeruginosa is a frequent cause of antibiotic-resistant infections. Although P. aeruginosa is intrinsically resistant to many antimicrobial agents, aminoglycosides are active against this organism in the absence of acquired resistance determinants and mutations. However, genes encoding aminoglycoside modifying enzymes (AMEs) are found in many strains that are resistant to these agents. We examined the prevalence of phenotypic resistance to the commonly used aminoglycosides gentamicin, tobramycin, and amikacin in a collection of 227 P. aeruginosa bloodstream isolates collected over two decades from a single U.S. academic medical institution. Resistance to these antibiotics was relatively stable over this time period. High-risk clones ST111 and ST298 were initially common but decreased in frequency over time. Whole genome sequencing identified relatively few AME genes in this collection compared to the published literature; only 14% of isolates contained an AME gene other than the ubiquitous aph(3’)-IIb. Of those present, only ant(2”)-Ia was associated with phenotypic resistance to gentamicin or to tobramycin. One extensively drug-resistant strain, PS1871, contained 5 AME genes, most of which were part of clusters of antibiotic resistance genes embedded within transposable elements. These findings suggest that AME genes play a relatively minor role in aminoglycoside resistance at our institution but that multidrug-resistant strains remain a problem.

The COVID-19 pandemic compounds stressors of daily life among American Indian/Alaska Natives. This study investigated the impact of COVID-19 among American Indian/Alaska Natives and non-Hispanic whites by examining depressive symptoms, overall stress, resilience, and coping, utilizing the Transactional Model of Stress and Coping. Of the 207 individuals participating in this study, 109 identified as American Indian/Alaska Native and 98 as non-Hispanic white. Despite demographic similarities, American Indian/Alaska Natives exhibited more stressors related to COVID-19 as well as higher depressive symptom scores compared to non-Hispanic whites. Furthermore, COVID-19 stressors were more positively correlated with depressive symptoms for American Indian/Alaska Natives than non-Hispanic whites. For American Indian/Alaska Natives, the predominant coping processes identified were planful problem solving, escape-avoidance, and self-controlling. This study provides data to support programs and policies centered on improving the psychosocial health for American Indians/Alaska Natives and decreasing COVID-19-related health disparities.

No abstract

This study was conducted to identify processes of coping with COVID-19 and determine their impact on emotional well-being for women of color in the United States. Data were collected from 368 women between May and July 2020 using an online survey guided by the Transactional Model of Stress and Coping, which included an assessment of COVID-19 stressors, Brief Encounter Psychosocial Instrument (BEPSI), 10-item Connor-Davidson Resilience Scale (CD-RISC-10), Ways of Coping Questionnaire (WCQ), and Center for Epidemiologic Studies Depression Scale (CES-D). Over half of the women were depressed (59.0%) and felt ill (69.3%) from the stress of COVID-19. Planful problem solving (M = 4.58, SD = 2.70) was the primary way to cope with COVID-19. A small, positive correlation existed between COVID-19 stressors and depressive symptoms (r = 0.27, p < .001). COVID-19 had a significant impact on the increase of stress (MI = 0.53, p < .001) and depressive symptoms (MI = 5.90, p < .001) as well as the decrease of resilience (MD = 2.17, p < .001) for women of color in the United States. These results can be translated into actionable care plans for clinicians and public health professionals that inform the development of tailored, culturally appropriate, equitable, and gender-specific mental health care for women of color in the age of COVID-19.